Anzeige
Mehr »
Sonntag, 24.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DUAC | ISIN: NL00150012L7 | Ticker-Symbol: KH6
Tradegate
22.08.25 | 18:31
21,600 Euro
+0,93 % +0,200
1-Jahres-Chart
NEWAMSTERDAM PHARMA COMPANY NV Chart 1 Jahr
5-Tage-Chart
NEWAMSTERDAM PHARMA COMPANY NV 5-Tage-Chart
RealtimeGeldBriefZeit
21,00021,60023.08.
21,20021,40022.08.

Aktuelle News zur NEWAMSTERDAM PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoPiramal, NewAmsterdam Pharma Open Dedicated OSD Form Suite1
NEWAMSTERDAM PHARMA Aktie jetzt für 0€ handeln
DoPiramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site250The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial...
► Artikel lesen
MoNewAmsterdam Pharma Company N.V.: NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib135-- Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia...
► Artikel lesen
15.08.NewAmsterdam Pharma Co N.V. - 8-K, Current Report1
11.08.Piper Sandler reiterates Overweight rating on NewAmsterdam Pharma stock1
08.08.What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co2
06.08.NewAmsterdam Pharma reports Q2 results1
06.08.NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results91-European marketing authorization application on track in 2H25 - - PREVAIL Phase 3 CVOT remains on track - - Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published...
► Artikel lesen
06.08.NewAmsterdam Pharma Co N.V. - 10-Q, Quarterly Report2
30.07.NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 20255
30.07.NewAmsterdam Pharma Co N.V. - 8-K, Current Report4
17.07.Goldman Sachs nimmt Beobachtung von NewAmsterdam Pharma mit "Neutral" auf6
17.07.Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating3
11.07.NewAmsterdam Pharma Co N.V. - 8-K, Current Report3
27.06.Thursday's Insider Moves: Big Buys at NewAmsterdam Pharma, CME Group5
17.06.Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug3
12.06.What Analysts Are Saying About NewAmsterdam Pharma Co Stock6
12.06.Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data2
12.06.NewAmsterdam Pharma stock maintains buy rating at Stifel on strong data2
12.06.NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel2
Weiter >>
66 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1